Streptococcus pneumoniae
 Articles that lack this notice, including many Eduzendium ones, welcome your collaboration! |
Classification
Higher order taxa
Domain: Bacteria
Phylum: Firmicutes
Class: Diplococci
Order: Lactobacillales
Family: Streptococcaceae
Genus: Streptococcus
Species
Species: S. pneumoniae
Description and significance
Streptococcus pneumoniae, also called pneumococcus, is a gram-positive, pathogenic bacterium capable of causing numerous infections. It the most common cause of pneumonia and bacterial meningitis, and is commonly found in the upper respiratory tract of humans. S. pneumoniae is shaped like a lancet, a type of knife with a short wide two-edged blade. It is alpha hemolytic (a classification method using the breakdown of red blood cells) and is usually between 0.5 and 1.25 micrometers in size.
S. pneumoniae was first isolated in 1881 simultaneously by U.S. Army physician George Sternberg and French chemist Louis Pasteur. In 1928 by Frederick Griffith and 1944 by Avery, MacLeod and McCarty, S. pneumoniae was used to prove that genetic material consists of DNA.
Genome structure
S. pneumoniae has a 2,160,837 base pair genome sequence. Its chromosome is circular and has 2236 coding regions. Approximately 5% of the genome is composed of insertion sequences that may contribute to genome rearrangements through uptake of foreign DNA. S. pneumoniae has shown a significant increase in antibiotic resistance over the past few decades, due to its rapid growth rate and genetic rearrangements.
Cell structure and metabolism
S. pneumoniae is completely surrounded by a capsule made up of polysaccharides. The capsule interferes with phagocytosis by preventing opsonization of its cells. The cell wall of S. pneumoniae is six layers thick and made up of peptidoglycan with teichoic and lipoteichoic acids. Within these acids are choline-binding proteins (CBPs), which adhere to choline receptors on human cells. S. pneumoniae has pili, which are hair-like structures extending from its surface. It also has more than 500 surface proteins, including five penicillin binding proteins (PBPs), two neuraminidases, an IgA protease, as well as choline-binding proteins as stated previously.
S. pneumoniae gains a substantial amount of carbon and nitrogen using extracellular enzyme systems which allow for the metabolism of polysaccharides and hexosamines. These systems also damage host tissues and facilitate colonization.
Ecology
S. pneumoniae is commonly found in the upper respiratory tract of humans, specifically the nasopharynx region. It is found in 5-10% of healthy adults, and 20-40% of healthy children. S. pneumoniae is non-pathogenic unless it travels outside the normal inhabited region, where it will then become pathogenic and cause different infections depending on the area in which it makes it way into.
S. pneumoniae sometimes shares its normal habitat with the pathogen Haemophilus influenzae. Individually each pathogen thrives on its own. However, when both pathogens inhabit the region at the same time, after 2 weeks only H. influenzae survives. Immune response caused by H. influenzae leads to the death of S. pneumoniae.
Pathology
Depending on where S. pneumoniae travels, different infections will occur. If it reaches the Eustachian tube or nasal sinuses, otitis media and sinusitis will result. If it enters the lungs, pneumonia will occur. If S. pneumoniae enters the bloodstream, bacteremia will occur and can subsequently result in meningitis, brain abscess, septic arthritis, or osteomyelitis. S. pneumoniae most commonly causes pneumonia and meningitis. Symptoms of pneumonia are cough producing green or yellow sputum, chills, chest pain, fever, and difficulty breathing. Symptoms of meningitis are severe headache, neck stiffness, and fever.
S. pneumoniae has several virulence factors which enable it to evade the human immune system. It has a polysaccharide capsule, which interferes with phagocytosis by preventing opsonization of its cells. It has pneumolysin, a protein that causes lysis of host cells and prevents activation of the complement pathway. It also has autolysin, which lyses its own cells to release its contents. Other virulence factors include hydrogen peroxide, pili, and choline binding protein.
Application to Biotechnology
Research using S. pneumoniae in the lab has been mainly for finding vaccines against it. The reason it is difficult to pinpoint a vaccination is due to the fact that over 90 serotypes of S. pneumoniae exist, and that immunization with a one serotype does not protect against infection with other serotypes. Vaccinations currently in use target multiple serotypes. Young children (under 60 months) are given a heptavalent pneumococcal conjugate vaccine (PCV 7) such as Prevnar. Adults are given a pneumococcal polysaccharide vaccine such as Pneumovax.
Current Research
S. pneumoniae continues to be highly pathogenic and resistant to many antibiotics. A recent study showed that a pneumococcal conjugate vaccine introduced in children in the year 2000 showed a significant decrease in effect after 4 years. The 7-Valent pneumococcal conjugate vaccine (PCV7) was introduced in children in 2000, and the proportion of S. pneumoniae isolates susceptible to the antibiotic was tested yearly. After 4 years, the proportion of susceptible isolates decreased significantly, showing that S. pneumoniae builds resistance to antibiotics fairly rapidly.
Not only is S. pneumoniae becoming resistant to many current antibiotics, new serotypes are still being discovered. A recent study found a new capsular serotype of S. pneumoniae. Researchers found a new subtype within serotype 6. Two subtypes (A & B) were already known, however a subtype C has now been discovered. This study showed that serotypes can be found within already established serotypes.
S. pneumoniae vaccines are typically injected into the body, however a study conducted research using vaccines administered using the intranasal route had successful results in animals. Using unencapsulated killed whole-cell pneumococci of the type 6B strain, researchers administered the vaccine intranasally into rats. The vaccine proved protect the animal from infection.[1]
References
- ↑ Malley, R., Lipsitch, M., Stack, A., Saladino, R., Fleisher, G., Pelton, S., Thompson, C., Briles, D., and Anderson, P. "Intranasal Immunization with Killed Unencapsulated Whole Cells Prevents Colonization and Invasive Disease by Capsulated Pneumococci". Infection and Immunity. August 2001. Vol. 69. p. 4870-4873.